Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $6 | $5 | $2 |
| G&A Expenses | $9 | $9 | $7 | $11 |
| SG&A Expenses | $9 | $9 | $7 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $15 | $12 | $13 |
| Operating Income | -$14 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$14 | -$15 | -$12 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |
| EPS | -17.59 | -23.01 | -22.36 | -24.96 |
| % Growth | 23.6% | -2.9% | 10.4% | – |
| EPS Diluted | -17.59 | -23.01 | -22.36 | -24.96 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $14 | $0 | $0 | $0 |
| EBITDA | $0 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |